Showing results (71-80 of 90) with videos related to
Sort By:
Pageof 9
Cancer|November 10, 2024
Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemiaCongxiao Zhang, Runxia Gu, Huijun Wang, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 30, 2014
[Characteristics and treatment outcomes in 822 adult patients with acute myeloid leukemia:a single center experience]Dong Lin, Chunlin Zhou, Hui Wei, et al.Frontiers in Oncology|June 21, 2021
Gene Deletions and Prognostic Values in B-Linage Acute Lymphoblastic LeukemiaQiuyun Fang, Yang Song, Xiaoyuan Gong, et al.Haematologica|March 19, 2026
The prognostic role of myeloid-related gene mutations in adult acute lymphoblastic leukemiaWenting Wang, Jiayuan Chen, Yan Li, et al.Journal of Cancer Research and Clinical Oncology|October 29, 2021
Health-related quality of life in children with chronic myeloid leukemia in the chronic phaseFangyuan Zheng, Xuelin Dou, Liqiang Zhang, et al.Haematologica|June 27, 2024
Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemiaYunfan Yang, Yuntao Liu, Hui Sun, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2020
Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid LeukemiaHui Wei, Ying Wang, Robert Peter Gale, et al.Leukemia|June 30, 2025
Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trialXiaoyuan Gong, Wenbing Liu, Yuntao Liu, et al.Experimental Hematology & Oncology|September 17, 2021
Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specifiedKaiqi Liu, Yan Li, Shaowei Qiu, et al.Experimental Hematology|February 1, 2021
Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1Hui Wei, Xueou Liu, Ying Wang, et al.Pageof 9